
Tackling unsolved challenges in complex human #diseases with unmet clinical needs using #PrecisionMedicine #AI #Immunometabolism
Blacksburg, VA
Joined December 2013
- Tweets5.6K
- Following3.8K
- Followers3.1K
- Likes1.9K
The NIMML Institute retweeted
Dr. Josep Bassaganya‑Riera is launching a clinical program advancing NIM‑1324 a next‑gen oral, once-daily LANCL2 therapeutic for IBD. NIM‑1324 targets both gut and extraintestinal disease through a systemic approach. Results will be presented at #DDW2026.
businesswire.com/news/home/2…
The NIMML Institute retweeted
Dr. Josep Bassaganya-Riera, our Founder & CEO, was featured on the Biotech Blueprint podcast, delving into the scientific underpinnings of how NImmune’s lead candidates outperform current IBD drugs in efficacy and safety. Listen here: open.spotify.com/show/6bn77q…
The NIMML Institute retweeted
Listen to Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, on @BiotechnologyPa’s Biotech Insiders podcast as he shares how AI is transforming drug development and why high-precision immunology is key to disrupting the I&I disease treatment paradigm. podcasts.apple.com/us/podcas…
The NIMML Institute retweeted
ICYMI: Eli Lilly and Nvidia recently announced a new partnership to leverage AI capabilities for drug discovery & development.
At NImmune, we've successfully demonstrated how advanced AI models can greatly accelerate therapeutic discovery & development. nimmunebio.com/the-nimml-ins…
The NIMML Institute retweeted
Listen to Dr. Josep Bassaganya-Riera, Founder & CEO of NImmune, on the Honestquo VC Podcast as he discusses pioneering tech in precision medicine and shares insights from his journey as a biotech founder.
Listen here: podcasts.apple.com/gh/podcas…
#Biopharma #AI #PrecisionMedicine
The NIMML Institute retweeted
Listen to our Founder & CEO, Dr. Josep Bassaganya-Riera, on the @BioWorld Insider podcast, where he discusses how NImmune is leveraging the TITAN-X AI platform to advance precision medicine in inflammatory and autoimmune diseases. Listen here: bioworld.com/media/podcasts/…
The NIMML Institute retweeted
Today on #WorldIBDDay, we stand with the global IBD community in the fight against Crohn’s disease and ulcerative colitis. At NImmune, our team is advancing omilancor, a first-in-class oral therapeutic targeting LANCL2, now in Phase 3.
The NIMML Institute retweeted
Thrilled to share that our Founder & CEO, Dr. Josep Bassaganya-Riera, was featured on @LaunchBio’s NextGen VC podcast to discuss his journey building Landos Biopharma from new scientific findings to a $600M market cap company. Listen here: launchbio.org/nextgen-vc-pod…
The NIMML Institute retweeted
Check out our Founder & CEO, Dr. Josep Bassaganya-Riera, on the Life Science & Biotech CEO Stories podcast as he shares his success story and how he's leading the charge in applying A.I. to biotech innovation. Listen here: biotechinsights.net/post/he-…
The NIMML Institute retweeted
We are pleased to share that NImmune will be attending #JPM2025 in San Francisco from January 13–16! We look forward to engaging in impactful conversations, connecting with industry leaders, and building our network to start 2025 on a strong note.
The NIMML Institute retweeted
A recent study from researchers at @CUNYNeuro identified LANCL2 as a new therapeutic target for Alzheimer’s disease and demonstrates the therapeutic efficacy of omilancor in a rat model. Read the full paper in @biorxivpreprint: biorxiv.org/content/10.1101/…
The NIMML Institute retweeted
Excited to be featured in Valley Business FRONT! Our CEO Dr. Bassaganya-Riera discusses Nimmune’s role in Virginia’s BioHealth innovation ecosystem. We’re pushing boundaries in immunology with AI-driven drug development and transformative clinical trials. issuu.com/berryfield5/docs/v…
The NIMML Institute retweeted
On Oct. 21, we acquired development and commercialization rights for omilancor in Greater China. We now wholly own global rights to omilancor, the best-in-class therapy for ulcerative colitis and other I&I indications. Read the full announcement: nimmunebio.com/nimmune-bioph…
The NIMML Institute retweeted
Research published in @J_Immunol validates NIM-1324 as the first LANCL2 agonist effective in systemic inflammation across 3 in vivo lupus models. Read more about how @NIMMLab is making groundbreaking mechanistic discoveries: nimmunebio.com/the-nimml-ins…
The NIMML Institute retweeted
NImmune is proud to participate in the UBS Virtual Biotechnology Private Company Symposium, Sept 18-19, 2024. Our team will be meeting with investors and industry leaders to discuss our innovative work in #biotech. Exciting times ahead! #UBSSymposium businesswire.com/news/home/2…
The NIMML Institute retweeted
We’re excited to partner with @BioTherap to accelerate our immunoregulatory drug pipeline. This collaboration enhances our precision medicine capabilities and further complements our work with @NIMMLab's TITAN-X A.I. Read more about the announcement here: businesswire.com/news/home/2…
The NIMML Institute retweeted
Excited to share that our Founder & CEO Dr. Josep Bassaganya-Riera, was featured on @BioEmprendedorx! He discusses @NImmuneBio’s work on biomarker-based therapies for inflammatory and autoimmune diseases, and our lead therapeutic for IBD, omilancor. bioemprendedores.es/episodio…
The NIMML Institute retweeted
Our Founder, Executive Chairman, & CEO Dr. Josep Bassaganya-Riera was named a VA Success Story by @vabio at THRiVE & shared his thoughts on the NImmune, @NIMMLab, & @BioTherap ecosystem & its critical work leading to the acquisition of Landos by AbbVie. linkedin.com/posts/nimmune-b…
The NIMML Institute retweeted
ICYMI: @BioBuzzMaryland sat down with Dr. Josep Bassaganya-Riera to discuss NImmune’s launch & how our Phase 3-ready lead candidate Omilancor could revolutionize the #IBD market, offering higher efficacy & stronger safety profiles than current treatments biobuzz.io/nimmune-biopharma…
The NIMML Institute retweeted
@NIMMLab developed a high-resolution ENteric Immunity Simulator (ENISI)-based model of the stomach for simulating the mucosal immune responses to #Hpylori infection @GigaScience ncbi.nlm.nih.gov/pmc/article…




















